Intraaortic Balloon Pumping
To the Editor:
In a well-executed technical contribution to the literature, Leinbach and colleagues reported early intraaortic balloon pumping (IABP) for anterior myocardial infarction.1 Dr. Scheidt's beautifully analytic editorial appropriately proposed randomized clinical trials but excused the absence of a control group in that study because it was "of course, in the nature of a pilot study." A major problem is symbolized by the words "of course," since other leading cardiologists continue to make "pilot study" a familiar disclaimer.2 Exemption of "pilot studies" represents a signiflcant aspect of the failure of many of our colleagues to commit themselves consistently to the principle of controlled clinical trials.
Leinbach and colleagues had no lack of technical capability in applying IABP, so their work might qualify as a "pilot study" only with reference to their new indication for IABP. Yet, even if technical feasibility in human beings had not already been shown, an appropriate controlled design is essential.
Chalmers3 has analyzed the pernicious influence of pilot studies pernicious, because they tend to convince investigators, on inadequate grounds, of the efficacy of their new treatment. Once convinced, they may find themselves ethically bound to use it in all patients, i.e., a control group is excluded because of personal ethics.
Absence of a control group leaves this IABP study, like uncontrolled surgical work, in the position of a technical tour de force. We cannot determine the net benefit (i.e., harm minus help) of any treatment at any time without an appropriate standard of comparison. It would have been better for the investigators to randomize their subjects to IABP or control to find out whether IABP for this proposed indication was causing net harm to some (or indeed all) of these infarct patients. Many other less traumatic interventions for which objective data like ST mapping seem to indicate improvement have not shown net long-term benefit in terms of morbidity and mortality. What actually happens to the patient is the proof desired, and we cannot know what this means without matched control patients. Indeed, the patients in this trial should have been given a 50-50 chance not to receive IABP, along with the same kind of explanation cited by the authors at the time of informed consent.' Scientific and ethical integrity would have been maintained by the straightforward acknowledgment that this was a promising treatment but its effect (in either direction) was undetermined. Thereafter, the patients who had IABP should have been randomized and those who did not separately analyzed. The die-hard exemption of technical procedures (e.g., surgery, IABP, pacing for new indications) from standards of proof equal to those for drugs is evidence of persistently "schizoid behavior"' among even our most accomplished colleagues. An analogous situation developed when good clinical electrophysiology led to sometimes indiscriminate permanent pacing for potential high grade atrioventricular block (prolonged H-V interval, etc.). The rush to apply that technique yielded to better evidence which, at last, significantly reduced what were considered to be urgent indications.4' Randomization at the outset would have given some patients a 50-50 chance not to acquire an additional disease: electronic pacemaker. Whenever an appropriate controlled trial of a new therapy or a new application of existing therapy can be designed, it is unscientific, unethical and, indeed, immoral not to do this.
The Food and Drug Administration ensures that the controlled clinical trial is state-of-the-art for pharmacologic interventions. Unfortunately, the natural guardians of the patient, i.e., hospital human trials committees and journal reviewers, have not universally recognized that at the level of standards of comparison all treatments are equal. A drug study with the design of this IABP study 1212 would have been rejected. The result is a reassertion of the technical feasibility of the procedurewell known previously. Only the publication filter can offer protection from widespread adoption of work by top ranking investigators which may have single, but vital flaw: an unacceptable standard of comparison. DAVID H. SPODICK, M.D., D.Sc. University of Massachusetts and St. Vincent Hospital Worcester, Massachusetts 01604
